LMDX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):

Stats
Today's Volume	120.55M
Average Volume	0.00
Market Cap	249.63M
EPS	$0 ( 2024-03-19 )
Next earnings date	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0140 (93.33%)

Volume Correlation

Long: 0.04 (neutral)

Short: -0.37 (neutral)

Signal:(34.365) Neutral

LumiraDx Limited Correlation

10 Most Positive Correlations
OZK	0.892
DDIV	0.888
PNFP	0.881
FTXO	0.88
PSCF	0.879
COLB	0.879
FITB	0.877
UG	0.877
ARQT	0.874
AIRG	0.87

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

LumiraDx Limited Correlation - Currency/Commodity

0.50
( weak )

0.58
( weak )

0.00
( neutral )

0.53
( weak )

-0.80
( moderate negative )

-0.47
( neutral )

LumiraDx Limited Financials

Annual	2022
Revenue:	$254.48M
Gross Profit:	$-35.30M (-13.87 %)
EPS:	$-1.590

Q2	2023
Revenue:	$21.00M
Gross Profit:	$-9.90M (-47.14 %)
EPS:	$-0.160

Q1	2023
Revenue:	$22.17M
Gross Profit:	$-1.76M (-7.93 %)
EPS:	$-0.140

Q4	2022
Revenue:	$41.12M
Gross Profit:	$-98.80M (-240.27 %)
EPS:	$-0.320

Financial Reports:

No articles found.

LumiraDx Limited

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.